{"id":"W2550819725","doi":"10.1136/annrheumdis-2016-eular.2021","title":"THU0138 Secondary Efficacy Results Up To Week 24 from A Phase III Study Comparing SB5 (An Adalimumab Biosimiar) with Adalimumab Reference Product in Patients with Moderate To Severe Rheumatoid Arthritis despite Methotrexate Therapy","year":2016,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of Toronto; Mount Sinai Hospital","funders":"","keywords":"Medicine; Adalimumab; Rheumatoid arthritis; Clinical endpoint; Internal medicine; Methotrexate; Surrogate endpoint; Physical therapy; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003379048,0.001517931,0.003445107,0.0007089241,0.0006313677,0.0009565012,0.0008519235,0.001428597,0.007754158],"category_scores_gemma":[0.002075874,0.0005168853,0.003387617,0.0004946136,0.0008784542,0.000911481,0.0004133208,0.003699466,0.00145266],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007032228,"about_ca_system_score_gemma":0.001077093,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000731251,"about_ca_topic_score_gemma":0.001455666,"domain_scores_codex":[0.9987509,0.0006185481,0.0001191194,0.0001686782,0.0001228885,0.0002198972],"domain_scores_gemma":[0.9978426,0.0006399381,0.0004729059,0.0001613017,0.0002568941,0.0006262728],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9092658,0.01640374,0.002920289,0.001177502,0.003226501,0.0001491766,0.00009729168,0.0008206892,0.01979303,0.0001097264,0.002151054,0.04388523],"study_design_scores_gemma":[0.4588935,0.4987136,0.02611497,0.00009299866,0.004546846,0.0002395831,0.00007312989,0.0006389836,0.006679567,0.0001765203,0.00377887,0.00005143854],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9790486,0.006317789,0.001176099,0.0005718499,0.0004116511,0.002502474,0.004985753,0.000186895,0.004798988],"genre_scores_gemma":[0.9830972,0.001634818,0.001403189,0.0007785542,0.0003527078,0.001731474,0.006218024,0.00004965936,0.004734281],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007754158,"threshold_uncertainty_score":0.02594018,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06699277095954076,"score_gpt":0.3212752334356977,"score_spread":0.2542824624761569,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}